Возможности использования ацетилсалициловой кислоты и других нестероидных противовоспалительных препаратов для уменьшения онкологического риска (обзор литературы)

Авторы

DOI:

https://doi.org/10.14739/2310-1210.2021.3.209851

Ключевые слова:

ацетилсалициловая кислота, нестероидные противовоспалительные препараты, онкологический риск

Аннотация

Цель работы – анализ и обобщение данных современной научной литературы о возможности использования ацетилсалициловой кислоты (АСК) и других нестероидных противовоспалительных препаратов (НПВП) для снижения онкологического риска.

Выводы. Хронический воспалительный процесс имеет важное значение для развития и прогрессирования опухолей. Ацетилсалициловая кислота и другие нестероидные противовоспалительные препараты способны через циклооксигеназный путь и другие механизмы уменьшать риск канцерогенеза. АСК и неаспириновые НПВП имеют практически исследованные возможности снижения риска развития онкологической патологии головы и шеи, лёгких, желудочно-кишечного тракта, молочных желез, яичников, простаты, кожи. Результаты применения АСК для первичной профилактики колоректального рака представлены в рекомендациях U. S. Preventive Services Task Force (2016) для определённых групп пациентов. Исследования свидетельствуют, что защитный потенциал АСК против различных видов рака неоднородный, зависит от популяции, клеточного типа рака, длительности приёма и использованных доз. Влияние неаспириновых НПВП на заболеваемость и прогноз более противоречиво.

Биографии авторов

В. В. Бугерук, Одесский национальный медицинский университет, Украина

канд. мед. наук, доцент каф. общей практики

Е. Б. Волошина, Одесский национальный медицинский университет, Украина

д-р мед. наук, профессор, зав. каф. общей практики

Л. И. Ковальчук, Одесский национальный медицинский университет, Украина

канд. мед. наук, доцент кафедры общей практики ОНМедУ

И. В. Балашова, Одесский национальный медицинский университет, Украина

канд. мед. наук, старший научный сотрудник, ассистент каф. общей практики

Е. В. Найдёнова, Одесский национальный медицинский университет, Украина

канд. мед. наук, ассистент каф. общей практики

Библиографические ссылки

Khandia, R., & Munjal, A. (2020). Chapter Six - Interplay between inflammation and cancer. In R. Donev (Ed.), Advances in protein chemistry and structural biology (Vol. 119, pp. 199-245). Academic Press. https://doi.org/10.1016/bs.apcsb.2019.09.004

Baron, J. A. (2003). Epidemiology of non-steroidal anti-inflammatory drugs and cancer. In A. J. Dannenberg & R. N. DuBois (Eds.), Progress in Experimental Tumor Research (Vol. 37, pp. 1-24). Basel, Karger. https://doi.org/10.1159/000071364

Zappavigna, S., Cossu, A. M., Grimaldi, A., Bocchetti, M., Ferraro, G. A., Nicoletti, G. F., Filosa, R., & Caraglia, M. (2020). Anti-Inflammatory Drugs as Anticancer Agents. International Journal of Molecular Sciences, 21(7), Article 2605. https://doi.org/10.3390/ijms21072605

Usman, M. W., Luo, F., Cheng, H., Zhao, J. J., & Liu, P. (2015). Chemopreventive effects of aspirin at a glance. Biochimica et Biophysica Acta, 1855(2), 254-263. https://doi.org/10.1016/j.bbcan.2015.03.007

Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123-134. https://doi.org/10.1038/nrc3004

Schrör, K., & Rauch, B. H. (2013). Acetylsalicylsäure und Prävention kolorektaler Karzinome. Der Internist, 54(7), 884-891. https://doi.org/10.1007/s00108-013-3311-y

Saxena, P., Sharma, P. K., & Purohit, P. (2020). A journey of celecoxib from pain to cancer. Prostaglandins & Other Lipid Mediators, 147, Article 106379. https://doi.org/10.1016/j.prostaglandins.2019.106379

Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015). Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology, 149(7), 1884-1895.e4. https://doi.org/10.1053/j.gastro.2015.07.064

Tołoczko-Iwaniuk, N., Dziemiańczyk-Pakieła, D., Nowaszewska, B. K., Celińska-Janowicz, K., & Miltyk, W. (2019). Celecoxib in Cancer Therapy and Prevention - Review. Current Drug Targets, 20(3), 302-315. https://doi.org/10.2174/1389450119666180803121737

Vallée, A., Lecarpentier, Y., & Vallée, J. N. (2019). Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs. Cells, 8(7), Article 726. https://doi.org/10.3390/cells8070726

Tsoi, K., Ho, J., Chan, F., & Sung, J. (2019). Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. International Journal of Cancer, 145(1), 267-273. https://doi.org/10.1002/ijc.32083

Loomans-Kropp, H. A., Pinsky, P., Cao, Y., Chan, A. T., & Umar, A. (2019). Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JAMA Network Open, 2(12), Article e1916729. https://doi.org/10.1001/jamanetworkopen.2019.16729

McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., … ASPREE Investigator Group. (2018). Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. The New England Journal of Medicine, 379(16), 1519-1528. https://doi.org/10.1056/NEJMoa1803955

Zheng, S. L., & Roddick, A. J. (2019). Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA, 321(3), 277-287. https://doi.org/10.1001/jama.2018.20578

de la Cour, C. D., Dehlendorff, C., Aalborg, G. L., von Buchwald, C., Friis, S., Verdoodt, F., & Kjaer, S. K. (2020). Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study. International Journal of Cancer, 146(8), 2139-2146. https://doi.org/10.1002/ijc.32544

Brusselaers, N., & Lagergren, J. (2018). Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open, 8(7), Article e021869. https://doi.org/10.1136/bmjopen-2018-021869

Drew, D. A., Cao, Y., & Chan, A. T. (2016). Aspirin and colorectal cancer: the promise of precision chemoprevention. Nature Reviews Cancer, 16(3), 173-186. https://doi.org/10.1038/nrc.2016.4

Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009). Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. Journal of the National Cancer Institute, 101(4), 256-266. https://doi.org/10.1093/jnci/djn485

Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. (1993). Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis. The New England Journal of Medicine, 328(18), 1313-1316. https://doi.org/10.1056/NEJM199305063281805

Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet, 376(9754), 1741-1750. https://doi.org/10.1016/S0140-6736(10)61543-7

Cao, Y., Nishihara, R., Wu, K., Wang, M., Ogino, S., Willett, W. C., Spiegelman, D., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2016). Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncology, 2(6), 762-769. https://doi.org/10.1001/jamaoncol.2015.6396

Friis, S., Riis, A. H., Erichsen, R., Baron, J. A., & Sørensen, H. T. (2015). Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Annals of Internal Medicine, 163(5), 347-355. https://doi.org/10.7326/M15-0039

Veettil, S. K., Nathisuwan, S., Ching, S. M., Jinatongthai, P., Lim, K. G., Kew, S. T., & Chaiyakunapruk, N. (2019). Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis. Cancer Management and Research, 11, 561-571. https://doi.org/10.2147/CMAR.S180261

(2016). Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force. Annals of Internal Medicine, 164(12), 1-22. https://doi.org/10.7326/P16-9015

Emilsson, L., Holme, Ø., Bretthauer, M., Cook, N. R., Buring, J. E., Løberg, M., Adami, H. O., Sesso, H. D., Gaziano, M. J., & Kalager, M. (2017). Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Alimentary Pharmacology & Therapeutics, 45(2), 193-204. https://doi.org/10.1111/apt.13857

Nan, H., Hutter, C. M., Lin, Y., Jacobs, E. J., Ulrich, C. M., White, E., Baron, J. A., Berndt, S. I., Brenner, H., Butterbach, K., Caan, B. J., Campbell, P. T., Carlson, C. S., Casey, G., Chang-Claude, J., Chanock, S. J., Cotterchio, M., Duggan, D., Figueiredo, J. C., Fuchs, C. S., … GECCO. (2015). Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. JAMA, 313(11), 1133-1142. https://doi.org/10.1001/jama.2015.1815

Song, Y., Zhong, X., Gao, P., Zhou, C., Shi, J., Wu, Z., Guo, Z., & Wang, Z. (2020). Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review. Frontiers in Endocrinology, 11, Article 3. https://doi.org/10.3389/fendo.2020.00003

Simon, T. G., Ma, Y., Ludvigsson, J. F., Chong, D. Q., Giovannucci, E. L., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., Zhang, X., & Chan, A. T. (2018). Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 4(12), 1683-1690. https://doi.org/10.1001/jamaoncol.2018.4154

Sun, J., Li, Y., Liu, L., Jiang, Z., & Liu, G. (2019). Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Medicine, 98(51), Article e18033. https://doi.org/10.1097/MD.0000000000018033

Yokoyama, K., Ishizuka, N., Uemura, N., Mizokami, Y., Hiraishi, H., Murata, M., Uchiyama, S., Teramoto, T., Shimada, K., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Ikeda, Y., & JPPP study group. (2018). Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Research and Practice in Thrombosis and Haemostasis, 2(2), 274-281. https://doi.org/10.1002/rth2.12097

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7-30. https://doi.org/10.3322/caac.21442

Hochmuth, F., Jochem, M., & Schlattmann, P. (2016). Meta-analysis of aspirin use and risk of lung cancer shows notable results. European Journal of Cancer Prevention, 25(4), 259-268. https://doi.org/10.1097/CEJ.0000000000000176

Zhang, W., Yi, L., Shen, J., Zhang, H., Luo, P., & Zhang, J. (2020). Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis. Journal of Cancer, 11(7), 1816-1827. https://doi.org/10.7150/jca.35003

Yi, L., Zhang, W., Zhang, H., Shen, J., Zou, J., Luo, P., & Zhang, J. (2018). Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug Design, Development and Therapy, 12, 2455-2466. https://doi.org/10.2147/DDDT.S169627

Lu, L., Shi, L., Zeng, J., & Wen, Z. (2017). Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget, 8(25), 40389-40401. https://doi.org/10.18632/oncotarget.16315

Kehm, R. D., Hopper, J. L., John, E. M., Phillips, K. A., MacInnis, R. J., Dite, G. S., Milne, R. L., Liao, Y., Zeinomar, N., Knight, J. A., Southey, M. C., Vahdat, L., Kornhauser, N., Cigler, T., Chung, W. K., Giles, G. G., McLachlan, S. A., Friedlander, M. L., Weideman, P. C., Glendon, G., … Terry, M. B. (2019). Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 21(1), Article 52. https://doi.org/10.1186/s13058-019-1135-y

Zhang, S. M., Cook, N. R., Manson, J. E., Lee, I. M., & Buring, J. E. (2008). Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. British Journal of Cancer, 98(5), 989-991. https://doi.org/10.1038/sj.bjc.6604240

Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., Denkert, C., Murray, E., Grieve, R., Coleman, R., Schmidt, M., Klare, P., Rezai, M., Rautenberg, B., Klutinus, N. … Bliss, J. (2018). Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). Abstracts: 2017 San Antonio Breast Cancer Symposium December 5-9 (Vol. 78, Issue 4, pp. GS3-03). https://doi.org/10.1158/1538-7445.sabcs17-gs3-03

Busby, J., Murray, L., Mills, K., Zhang, S. D., Liberante, F., & Cardwell, C. R. (2018). A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. Pharmacoepidemiology & Drug Safety, 27(1), 78-86. https://doi.org/10.1002/pds.4345

Zhang, D., Bai, B., Xi, Y., Wang, T., & Zhao, Y. (2016). Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecologic Oncology, 142(2), 368-377. https://doi.org/10.1016/j.ygyno.2016.04.543

Hannibal, C. G., Dehlendorff, C., & Kjaer, S. K. (2018). Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark. Gynecologic Oncology, 151(3), 513-518. https://doi.org/10.1016/j.ygyno.2018.09.022

Verdoodt, F., Dehlendorff, C., Friis, S., & Kjaer, S. K. (2018). Non-aspirin NSAID use and ovarian cancer mortality. Gynecologic Oncology, 150(2), 331-337. https://doi.org/10.1016/j.ygyno.2018.06.018

Thapa, D., & Ghosh, R. (2015). Chronic inflammatory mediators enhance prostate cancer development and progression. Biochemical Pharmacology, 94(2), 53-62. https://doi.org/10.1016/j.bcp.2014.12.023

Shang, Z., Wang, X., Yan, H., Cui, B., Wang, Q., Wu, J., Cui, X., Li, J., Ou, T., & Yang, K. (2018). Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis. Frontiers in Oncology, 8, Article 437. https://doi.org/10.3389/fonc.2018.00437

Hurwitz, L. M., Joshu, C. E., Barber, J. R., Prizment, A. E., Vitolins, M. Z., Jones, M. R., Folsom, A. R., Han, M., & Platz, E. A. (2019). Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study. Cancer Epidemiology, Biomarkers & Prevention, 28(3), 563-569. https://doi.org/10.1158/1055-9965.EPI-18-0965

Zhou, J., Xia, S., Li, T., & Liu, R. (2019). Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis. BMC Cancer, 19(1), Article 1186. https://doi.org/10.1186/s12885-019-6415-5

Muranushi, C., Olsen, C. M., Pandeya, N., & Green, A. C. (2015). Aspirin and Nonsteroidal Anti-Inflammatory Drugs Can Prevent Cutaneous Squamous Cell Carcinoma: a Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 135(4), 975-983. https://doi.org/10.1038/jid.2014.531

Ma, Y., Yu, P., Lin, S., Li, Q., Fang, Z., & Huang, Z. (2020). The association between nonsteroidal anti-inflammatory drugs and skin cancer: Different responses in American and European populations. Pharmacological Research, 152, Article 104499. https://doi.org/10.1016/j.phrs.2019.104499

Johannesdottir, S. A., Chang, E. T., Mehnert, F., Schmidt, M., Olesen, A. B., & Sørensen, H. T. (2012). Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer, 118(19), 4768-4776. https://doi.org/10.1002/cncr.27406

Elmets, C. A., Viner, J. L., Pentland, A. P., Cantrell, W., Lin, H. Y., Bailey, H., Kang, S., Linden, K. G., Heffernan, M., Duvic, M., Richmond, E., Elewski, B. E., Umar, A., Bell, W., & Gordon, G. B. (2010). Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the National Cancer Institute, 102(24), 1835-1844. https://doi.org/10.1093/jnci/djq442

Опубликован

2021-06-07

Выпуск

Раздел

Обзоры